Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
Rhea-AI Summary
Immuneering (Nasdaq: IMRX) will host a conference call and live webcast on January 7, 2026 at 4:00 p.m. ET to present updated 12-month overall survival (OS) results from its ongoing Phase 2a trial testing atebimetinib + modified Gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients.
The company said the webcast will be archived in its Investor Relations Events & Presentations section. Management highlighted confidence in atebimetinib’s potential to extend and improve patient survival and plans to discuss the 12-month OS update during the presentation.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
IMRX gained 4.6% while several biotech peers also traded higher (e.g., RCKT +7.95%, TECX +8.41%, LRMR +9.89%), but no coordinated sector momentum was flagged by the scanner.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 17 | Phase 3 alignment | Positive | -4.2% | Regulatory alignment and Phase 3 plan for atebimetinib + mGnP. |
| Dec 16 | Index inclusion | Positive | -0.7% | Planned addition to the Nasdaq Biotechnology Index. |
| Nov 25 | Conference appearance | Neutral | -0.7% | Participation in Piper Sandler healthcare conference and webcast. |
| Nov 12 | Earnings & clinical | Positive | -1.8% | Q3 2025 results with positive survival data and major financings. |
| Nov 04 | Earnings preview | Neutral | +0.5% | Scheduling Q3 call with new clinical case studies. |
Recent positive strategic and clinical updates have often met with flat-to-negative next-day moves, indicating a pattern of price divergence from seemingly favorable news.
Over the last six weeks, Immuneering reported multiple clinical and corporate milestones. On Nov 12, Q3 2025 results highlighted strong Phase 2a pancreatic data and a strengthened cash position into 2029, yet shares fell 1.78%. Subsequent announcements on index inclusion (Dec 16) and Phase 3 alignment with FDA/EMA (Dec 17) also saw modest declines. Earlier conference and earnings scheduling items produced minimal reactions. Today’s call announcement for 12‑month overall survival data continues the sequence of staged updates around the atebimetinib program.
Regulatory & Risk Context
An effective Form S-3 filed on Aug 13, 2025 registered up to $300,000,000 of securities, including an equity distribution agreement for up to $100,000,000 of Class A common stock within that total. The company has already used this shelf via at least 2 prospectus supplements (Form 424B5), providing flexibility to raise additional capital as development of atebimetinib advances.
Market Pulse Summary
This announcement schedules release of 12‑month overall survival data from the Phase 2a atebimetinib + mGnP trial in first-line pancreatic cancer on January 7, 2026. It extends a sequence of OS-focused updates that previously highlighted encouraging 6‑ and 9‑month outcomes and regulatory alignment for a Phase 3 study. Investors may track the durability of survival benefits, safety profile, and how results inform Phase 3 design, while also watching future financing activity under the $300,000,000 shelf registration.
Key Terms
overall survival medical
os medical
phase 2a medical
AI-generated analysis. Not financial advice.
NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it will host a conference call and live webcast at 4:00 p.m. ET on Wednesday, January 7, 2026 to provide an update on 12-month overall survival (OS) from its ongoing Phase 2a clinical trial of atebimetinib + modified Gemcitabine / nab-paclitaxel (mGnP) in first-line pancreatic cancer patients.
“We are excited to share updated overall survival data from our ongoing Phase 2a trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients,” said Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of Immuneering. “We are increasingly confident in atebimetinib’s ability to extend and improve the lives of patients with pancreatic cancer.”
The conference call will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation
Immuneering is a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve durability and tolerability across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. Atebimetinib is currently planned to be evaluated in a Phase 3 trial in first-line pancreatic cancer, which is expected to begin dosing in mid-2026. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.
Forward-Looking Statements
This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: the treatment potential of atebimetinib, alone or in combination with other agents to treat cancer, including modified Gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer; the timing of future data updates.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.
These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended September 30, 2025, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Media Contact:
Carson Creehan
202-878-8330
Carson.creehan@padillaco.com
Investor Contact:
Courtney Dugan
917-971-3466
Cdugan@immuneering.com
Laurence Watts
619-916-7620
laurence@newstreetir.com
FAQ
When will Immuneering (IMRX) present the 12-month OS data from the Phase 2a pancreatic cancer trial?
What specific data will Immuneering (IMRX) discuss on January 7, 2026?
How can investors access the Immuneering (IMRX) webcast for the January 7, 2026 presentation?
What is the trial regimen being updated by Immuneering (IMRX) on January 7, 2026?
Will Immuneering management comment on clinical implications during the January 7, 2026 call?
